A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of avonex in patients with multiple sclerosis
Overview of attention for article published in Clinical Therapeutics, April 2004
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (92nd percentile)
-
High Attention Score compared to outputs of the same age and source (94th percentile)
Readers on
- mendeley
- 24 Mendeley